Induction of the estrogen specific mitogenic response of MCF-7 cells by selected analogues of estradiol-17β: A 3D QSAR study

Journal of Medicinal Chemistry

Volumn 40, Issue 22, 1997, Pages 3659-3669

  Wiese, Thomas E ^a,c   Polin, Lisa A ^a   Palomino, Eduardo ^b   Brooks, S C ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Walker Cancer Research Institute   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTRADIOL DERIVATIVE; ESTROGEN RECEPTOR;

ARTICLE; BREAST CANCER; HUMAN; HUMAN CELL; MITOGENESIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ACTIVITY RELATION;

BREAST NEOPLASMS; ESTRADIOL; ESTROGENS; HUMANS; MODELS, MOLECULAR; RECEPTORS, ESTROGEN; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0030660115     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9703294     Document Type: Article

References (61)

1. Agarwal, M. K.; Raynaud, J. P. Steroid antagonists. FEBS Lett. 1989, 245, 1-3.
2. Katzenellenbogen, B. S.; Montano, M. M.; Ekena, K.; Herman, M. E.; McInerney, E. M. Antiestrogens-mechanisms of action and resistance in breast cancer. Breast Cancer Res. Treat. 1997, 44, 23-38.
3. Jordan, V. C. Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res. Treat. 1994, 31, 41-52.
4. Murphy, C. S.; Jordan, V. C. Structural components necessary for the antiestrogenic activity of tamoxifen. J. Steroid. Biochem. 1989, 34, 407-411.
5. Magarian, R. A.; Overacre, L. B.; Singh, S.; Meyer, K. L. The medicinal chemistry of nonsteroidal antiestrogens: A review. Curr. Med. Chem. 1994, 1, 61-104.
6. Raynaud, J. P.; Ojasoo, T.; Bouton, M. M.; Bignon, E.; Pons, M.; Crastes de Paulet, A. Structure activity relationships of steroid estrogens. In Estrogens in the Environment II: Influences on development; McLachlan, J. A., Eds.; Eisevier Science Publishing Co., Inc.: New York, 1985; pp 24-42.
7. Bignon, E.; Pons, M.; De Paulet, A. C.; Doré J-C; Gilbert, J.; Abecassis, J.; Miquel J.-F.; Ojasoo, T.; Raynaud J.-P. Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth. J. Med. Chem. 1989, 32, 2092-2103.
8. Etienne, M. C.; Milano, G.; Fischel, J. L.; Frenay, M.; François, E.; Formento, J. L.; Gioanni, J.; Namer, M. Tamoxifen metabolism: Pharmacokinetic and in vitro study. Br. J. Cancer 1989, 60, 30-35.
9. Wakeling, A. E.; Bowler, J. Steroidal pure antioestrogens. J. Endocrinol. 1987, 112, R7-R10.
10. Wakeling, A. E.; Bowler, J. Novel antioestrogens without partial agonist activity. J. Steroid Biochem. 1988, 31, 645-653.
11. Bowler, J.; Lilley, T. J.; Pittam, J. D.; Wakeling, A. E. Novel Steroidal pure antiestrogens. Steroids 1989, 54, 71-99.
12. Agarwal, M. K. Steroid receptor structure and antihormone drug design. Biochem. Pharmacol. 1992, 43, 2299-2306.
13. Gottardis, M. M.; Jiang S.-Y.; Jeng M.-H.; Jordan, V. C. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res. 1989, 49, 4090-4093.
14. Gottardis, M. M.; Wagner, R. J.; Borden, E. C.; Jordan, V. C. Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Res. 1989, 49, 4765-4769.
15. Thompson, E. W.; Katz, D.; Shima, T. B.; Wakeling, A. E.; Lippman, M. E.; Dickson, R. B. ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness. Cancer Res. 1989, 49, 6929-6934.
16. Wakeling, A. E. Comparative studies on the effects of Steroidal and nonsteroidal oestrogen antagonists on the proliferation of human breast cancer cells. J. Steroid Biochem. 1989, 34, 183-188.
17. Pons, M.; Bignon, E.; Crastes de Paulet, A.; Gilbert, J.; Ojasoo, T.; Raynaud, J. P. Hydroxylated triphenylacrylonitriles adopt a unique orientation within the binding site of the estrogen receptor. J. Steroid Biochem. 1990, 36, 391-397.
18. Wiseman, L. R.; Wakeling, A. E.; May, F. E. B.; Westley, B. R. Effects of the antioestrogen, ICI 164,384, on oestrogen induced RNAs in MCF-7 cells. J. Steroid Biochem. 1989, 33, 1-6.
19. Ratajczak, T.; Wilkinson, S. P.; Brockway, M. J.; Hähnel, R.; Moritz, R. L.; Begg, G. S.; Simpson, R. J. The interaction site for tamoxifen aziridine with the bovine estrogen receptor. J. Biol. Chem. 1989, 264, 13453-13459.
20. Castellano-Díaz, E.; González-Quijano, M. L; Limiñana, J. M.; Díaz-Chico, B. N. Tamoxifen decreases the estradiol induced progesterone receptors by interfering with nuclear estrogen receptor accumulation. J. Steroid Biochem. 1989, 33, 133-139.
21. McCague, R.; Leclercq, G.; Legros, N.; Goodman, J.; Blackburn, G. M.; Jarman, M.; Foster, A. B. Derivitives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent. J. Med. Chem. 1989, 32, 2527-2533.
22. Gibson, M. K.; Nemmers, L. A.; Beckman, W. J.; Davis, V. L.; Curtis, S. W.; Korach, K. S. The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 1991, 129, 2000-2010.
23. Gronemeyer, H. Transcription activation by estrogen and progesterone receptors. Annu. Rev. Genet. 1991, 25, 89-123.
24. Webster, N. J. G.; Green, S.; Jin, J. R.; Chambon, P. The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation factor. Cell 1988, 54, 199-207.
25. Berry, M.; Metzger, D.; Charnbon, P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 1990. 9, 2811-2818.
26. Brooks, S. C.; Wappler, N. L.; Corombos, J. D.; Doherty, L. M.; Horwitz, J. P. Estrogen structure-receptor function relationships. In Recent Advances in Steroid Hormone Action; Moudgil, V. K., Eds.; Walter de Gruyter & Co.: Berlin, 1987.
27. Brooks S. C.; Horwitz, J. P.; Odden, D.; Corbett, T. A-ring substituted estrogens as inhibitors of the MXT transplantable mammary ductal carcinoma. Cancer Res. 1987, 47, 4623-4629.
28. VanderKuur, J. A.; Wiese, T.; Brooks, S. C. Influence of estrogen structure on nuclear binding and progesterone receptor induction by the receptor complex. Biochemistry 1993, 32, 7002-7008.
29. Pilat, M. J.; Hafner, M. S.; Kral, L. G.; Brooks, S. C. Differential induction of pS2 and cathepsin D mRNAs by structurally altered estrogens. Biochemistry 1993, 32, 7009-7015.
30. VanderKuur, J. A.; Hafner, M. S.; Christman, J. K.; Brooks, S. C. Effects of estradiol-17β analogues on activation of estrogen response element regulated chloramphenicol acetyltransferase expression. Biochemistry 1993, 32, 7016-7021.
31. VanderKuur, J. A.; Brooks, S. C. Effect of A-ring isomers of estradiol-17β on gene products in MCF-7 cells. Steroids 1994, 59, 548-553.
32. Davis, M. D.; Butler, W. B.; Brooks, S. C. Induction of tissue plasminogen activator mRNA and activity by structurally altered estrogens. J. Steroid Biochem. Mol. Biol. 1995, 52, 421-430.
33. Palomino, E.; Heeg, M. J.; Horwitz, J. P.; Brooks, S. C. Binding, x-ray and NMR studies of the three A-ring isomers of natural estradiol. J. Steroid Biochem. 1990, 35, 219-229.
34. Wiese, T. E.; Brooks, S. C. Molecular modeling of steroidal estrogens: Novel conformations and their role in bioiogical activity. J. Steroid Biochem. Mol. Biol. 1994, 50, 61-73.
35. Horwitz, J. P.; lyer, V. K.; Vardhan, H. B.; Corombos, J.; Brooks, S. C. In Vitro inhibition of estrogen sulfoconjugation by some 2-and 4-substituted estra-1,3,5(10)-trien-17β-ols. J. Med. Chem. 1986, 29, 692-698.
36. Iriarte, J.; Ringold, H. J.; Djerassi, C. Synthesis of ring B oxygenated estrogens. J. Am. Chem. Soc. 1958, 80, 6015-6010.
37. Brooks, S. C.; Horwitz, J. P. Compositions inhibiting murine MXT ductal carcinoma. US Patent 4,636,496, 1987.
38. Hecker, E. New estrane derivitives with various substituents in the 3-position. Chem. Ber. 1962, 95, 977-984.
39. Tomson, A. J.; Horwitz, J. P. Some 2 and 3 substituted estrone-3-methylethers. J. Org. Chem. 1959, 24, 2056-2063.
40. Palomino, E.; Heeg, M. J.; Horwitz, J. P.; Polin, L.; Brooks, S. C. Skeletal conformations and receptor binding of some 9,11-modified estradiols. J. Steroid Biochem. Mol. Biol. 1994, 50, 75-84.
41. Wiese, T. E.; Kral, L. G.; Dennis, K. E.; Butler, W. B.; Brooks, S. C. Optimization of estrogen growth response in MCF-7 cells. In Vitro Cell. Dev. Biol. 1992, 28A, 595-602.
42. Butler, W. B.; Berlinski, P. J.; Hillman, R. M.; Kelsey, W. H.; Toenniges, M. M. Relation of in vitro properties to tumorigenicity for a series of sublines of the human breast cancer cell line MCF-7. Cancer Res. 1986, 46, 6339-6348.
43. Butler, W. B. Preparing nuclei from cells in monolayer cultures suitable for counting and for following synchronized cells through the cell cycle. Anal. Biochem. 1984, 141, 70-73.
44. Sokal, R. R.; Rohlf, F. J. In Biometry, 2nd ed.; W. H. Freeman and Company: San Francisco, 1981; pp 764-765.
45. Cramer, R. D. I.; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA), 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
46. Wold, S.; Albano, C.; Dunn, W. J., III; Edlund, U.; Esbensen, K.; Geladi, P.; Hellberg, S.; Johansson, E.; Lindberg, W.; Sjostrom. M. Multivariate data analysis in chemistry. In Chemometrics, Mathematics and Statistics in Chemistry; B. R. Kowalski, B. R., Ed.; D. Reidel Publishing Company: Dordrecht, 1984; pp 17-95.
47. Stahle, L; Wold, S. Multivariate data analysis and experimental design in biomedical research. Prog. Med. Chem. 1988, 25, 290-338.
48. Cramer, R. D., III; Bunce, J. D.; Patterson, D. E. Cross-validation, bootstrapping, and partial least squares compaired with multiple regression in conventional QSAR studies. Quant Struct.-Act. Relat. 1988, 7, 18-25.
49. Stewart, J. J. P. MOPAC: A semiempirical molecular orbital program. J. Comput.-Aided Mol. Des. 1990, 4, 1-105.
50. Anstead, G. M.; Carlson, K. E.; Katzenellenbogen, J. A. The estradiol pharmacophore: Ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 1997, 62, 268-303.
51. Palomino, E.; Heeg, M. J.; Pilat, M. J.; Hafner, M.; Polin, L.; Brooks, S. C. Crystal structure, receptor binding, and gene regulation of 2- and 4-nitroestradiols. Steroids 1996, 61, 670-676.
52. Besler, B. H.; Merz, K. M.; Kollman, P. A. Atomic charges derived from semiempirical methods. J. Comput. Chem. 1990, 11, 431-439.
53. Merz, K. M. Analysis of a large data base of electrostatic potential derived atomic charges. J. Comput. Chem. 1992, 13, 749-767.
54. Kearsley, S. K.; Smith, G. M. An alternative method for the alignment of molecular structures: Maximizing electrostatic and steric overlap. Tetrahedron Comput. Methodol. 1990, 3, 615-633.
55. Gantchev, T. G.; Ali, H.; van Lier, J. E. Quantative structure-activity relationships/comparative molecular field analysis (QSAR/ CoMFA) for receptor-binding properties of halogenated estradiol derivatives. J. Med. Chem. 1994, 37, 4164-4176.
56. Kellogg, G. E.; Semus, S. F.; Abraham, D. J. HINT: A new method of empirical hydrophobic field calculation for CoMFA. J. Comput.-Aided Mol. Des. 1991, 5, 545-552.
57. Calder, J. A.; Wyatt, J. A.; Frenkel, D. A.; Casida, J. E. CoMFA validation of the superposition of six classes of compounds which block GABA receptors non-competitively. J. Comput.-Aided Mol. Des. 1993, 7, 45-60.
58. Horwitz, J. P.; Massova, I.; Wiese, T. E.; Wozniak, A. J.; Corbett, T. H.; Sebolt-Leopold, J. S.; Capps, D. B.; Leopold, W. R. Comparative molecular field analysis of in vitro growth inhibition of L1210 and HCT-8 cells by some pyrazoloacridines. J. Med. Chem. 1993, 36, 3511-3516.
59. Horwitz, J. P.; Massova, L; Wiese, T. E.; Besler, B. H.; Corbett, T. H. Comparative molecular field analysis of the antitumor activity of 9H-thioxanthen-9-one derivatives against pancreatic ductal carcinoma 03 [published erratum appears in J. Med. Chem. 1994, 37 (19), 3196]. J. Med. Chem. 1994, 37, 781-786.
60. Horwitz, J. P.; Massova, L; Wiese, T. E.; Besler, B. H.; Corbett, T. H. Comparative molecular field analysis of the antitumor activity of 9H-thioxanthen-9-one derivatives against pancreatic ductal carcinoma 03 [published erratum appears in J. Med. Chem. 1994, 37 (19), 3196]. J. Med. Chem. 1994, 37, 781-786.
61. Hahn, M. Receptor surface models. 1. Definition and construction. J. Med. Chem. 1995, 38, 2080-2090.